Evotec Nominates Dr. Wolfgang Hofmann to Board, Reaches Agreement with MAK Capital
Evotec SE nominates Dr. Wolfgang Hofmann as independent board member and enters cooperation agreement with key shareholder MAK Capital to enhance governance and support transformation.
Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) announced the nomination of Dr. Wolfgang Hofmann for election as an independent member of the Supervisory Board at the company’s upcoming Annual General Meeting (AGM) on June 11, 2026. The AGM agenda also includes the previously announced nomination of Dieter Weinand as Chairman of the Supervisory Board, as well as a proposal to increase the board size from six to seven members.
Following constructive discussions, Evotec has entered into a cooperation agreement with MAK Capital Fund LP, a key shareholder. Under the agreement, MAK Capital has agreed to customary voting and cooperation commitments, reflecting what the company describes as a commitment to open shareholder dialogue.
“We are pleased to nominate Wolfgang for election at the upcoming AGM,” said Prof. Dr. Iris Low-Friedrich, Chairwoman of Evotec’s Supervisory Board. “His appointment would contribute oversight and governance capabilities through additional industry, scientific and governance expertise, complementing our existing Board structure as we continue to implement our transformation plans to grow shareholder value.”
The nomination comes at a pivotal time for Evotec, a life science company pioneering drug discovery and development through AI-driven innovation and advanced technologies. The company’s expertise spans small molecules, biologics, cell therapies, and other modalities, supported by proprietary platforms such as Molecular Patient Databases and iPSC-based disease modeling. Evotec works with all top 20 pharma companies and over 800 biotechs, academic institutions, and healthcare stakeholders.
Michael A. Kaufman, Chief Executive Officer of MAK Capital, welcomed the nomination: “We appreciate the constructive dialogue and welcome Wolfgang’s nomination to the Supervisory Board. We look forward to continuing our collaboration with the Supervisory Board and Management Board to support Evotec's ongoing transformation.”
The agreement with MAK Capital underscores Evotec’s commitment to shareholder engagement and long-term value creation. The proposed expansion of the Supervisory Board to seven members is intended to support effective oversight as the company executes its transformation plans. For more information about Evotec, visit www.evotec.com.
The AGM will vote on the appointments and the expansion, which are seen as key steps to strengthen governance and align with investor interests. Dr. Hofmann’s nomination brings additional expertise that could help guide Evotec through its next phase of growth, focusing on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.